← The SEC Ephemeris: the whole map
Bristol-Myers Squibb dapagliflozin
In the graph: all 7 documents (196 pages).
- Application
- NDA 202293
- Ticker
- BMY, CELG-RI
- Product
- dapagliflozin
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- January 17, 2012
From FDA letters and SEC filings. Not investment or medical advice.